A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

Abstract Echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) rearrangements are found in ~ 5% of patients with non‐small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so‐called ALK‐positive NSCLC. In cases...

Full description

Bibliographic Details
Main Authors: Yuki Matsumura, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Yuki Ozaki, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Thoracic Cancer
Subjects:
alectinib‐resistant lung adenocarcinoma
ceritinib
EML4‐ALK rearrangement
Online Access:https://doi.org/10.1111/1759-7714.14058

Internet

https://doi.org/10.1111/1759-7714.14058

Similar Items